GlassScriptPhysician profile
Neema Reddy
NPI 1053416743
$1,947.18
in general payments reported to CMS, 2019-2025
23 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.55 · 2020: $258 · 2021: $147 · 2022: $353 · 2023: $396 · 2024: $393 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,144.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $288.32 | 2021-2024 | |
| Lilly USA, LLC | $258.32 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Exact Sciences Corporation | $230.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $187.87 | 2020-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $145.56 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $144.91 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.64 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $85.00 | 2022 | |
| Amarin Pharma, INC. | $78.66 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $75.23 | 2023-2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $57.73 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $52.18 | 2024-2025 | |
| Heartflow, INC. | $42.57 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.48 | 2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $30.86 | 2025 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $28.16 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $19.40 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $18.25 | 2023 | |
| Gilead Sciences, INC. | $16.82 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.83 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.46 | 2021 | |
| Zealand Pharma US, INC. | $15.40 | 2021 | |
| Philips North America LLC | $14.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neema Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.